

NERVGEN PHARMA CORP.

Condensed Consolidated Interim Statements of Financial Position

(Expressed in Canadian dollars)

(Unaudited)

as at

June 30, 2019

December 31, 2018

\$

\$

Assets

Current assets

Cash	8,270,311	2,474,340
Accounts receivable	60,863	25,843
Prepays (Notes 6, 11)	86,267	49,375
	8,417,441	2,549,558

Non-current assets

Intangible assets (Note 7)	528,719	547,829
	528,719	547,829
	8,946,160	3,097,387

Liabilities

Current liabilities

Accounts payable and accrued liabilities (Note 8)	224,515	390,802
Due to related parties (Note 11)	102,752	58,074
	327,267	448,876

Non-current liabilities

License fee payable (Note 7)	-	134,230
	-	134,230
	327,267	583,106

Shareholders' Equity

Common shares (Note 9)	13,331,171	3,846,630
Reserves (Note 10)	1,204,615	37,947
Deficit	(5,916,893)	(1,370,296)
	8,618,893	2,514,281
	8,946,160	3,097,387

Nature of business (Note 1)

Subsequent events (Note 13)

Approved by the Board

/s/ William J. Radvak Director

/s/ Brian E. Bayley Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements